Re: Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5

Samir S. Taneja

doi:10.1016/j.juro.2015.07.010

Re: Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5

Samir S. Taneja

Biomedical Engineering

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Number of pages	1
Journal	Journal of Urology
Volume	194
Issue number	4
DOIs	https://doi.org/10.1016/j.juro.2015.07.010
State	Published - Oct 1 2015

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.juro.2015.07.010

Cite this

Re: Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. / Taneja, Samir S.
In: Journal of Urology, Vol. 194, No. 4, 01.10.2015.

Research output: Contribution to journal › Comment/debate › peer-review

@article{3b5051f8f44f45bb92684a39fe4fa470,

title = "Re: Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5",

author = "Taneja, {Samir S.}",

year = "2015",

month = oct,

day = "1",

doi = "10.1016/j.juro.2015.07.010",

language = "English (US)",

volume = "194",

journal = "Journal of Urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Re

T2 - Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5

AU - Taneja, Samir S.

PY - 2015/10/1

Y1 - 2015/10/1

UR - http://www.scopus.com/inward/record.url?scp=84941548966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941548966&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2015.07.010

DO - 10.1016/j.juro.2015.07.010

M3 - Comment/debate

C2 - 26382777

AN - SCOPUS:84941548966

SN - 0022-5347

VL - 194

JO - Journal of Urology

JF - Journal of Urology

IS - 4

ER -

Re: Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this